TY  - JOUR
AU  - Arriola, Edurne
AU  - Garcia-Gomez, Ramon
AU  - Diz, Pilar
AU  - Majem, Margarita
AU  - Martinez-Aguillo, Maite
AU  - Valdivia, Javier
AU  - Paredes, Alfredo
AU  - Sanchez-Torres, Jose Miguel
AU  - Peralta-Muñoz, Sergio
AU  - Barneto, Isidoro
AU  - Gutierrez, Vanesa
AU  - Andrade-Santiago, Jesus Manuel
AU  - Aparisi, Francisco
AU  - Isla, Dolores
AU  - Ponce, Santiago
AU  - Vicente-Baz, David
AU  - Artal, Angel
AU  - Amador, Mariluz
AU  - Provencio, Mariano
PY  - 2018
DO  - 10.1186/s12885-018-4004-7
UR  - http://hdl.handle.net/10668/12063
T2  - BMC cancer
AB  - Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used...
LA  - en
PB  - BioMed Central
KW  - Chemotherapy
KW  - Clinical management
KW  - EGFR tyrosine kinase inhibitors (TKIs)
KW  - Epidermal growth factor receptor (EGFR) gene mutation
KW  - Non-small-cell lung cancer (NSCLC)
KW  - Aged
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Disease-Free Survival
KW  - ErbB Receptors
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Gefitinib
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Neoplasm Staging
KW  - Protein Kinase Inhibitors
KW  - Quinazolines
KW  - Spain
KW  - Treatment Outcome
TI  - Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
TY  - research article
VL  - 18
ER  -